Coiled Therapeutics PLC is a biotechnology company focused on developing AO-252, a small molecule inhibitor targeting the TACC3 protein, which is over-expressed in various cancer cells. The company holds an exclusive worldwide license for AO-252, which has demonstrated preclinical efficacy in treating ovarian, triple negative breast, endometrial, gastric, and prostate cancers, as well as brain metastases. Coiled Therapeutics is engaged in clinical trials for AO-252 in advanced solid tumors, aiming to address significant unmet medical needs in oncology.